Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8748 vs Aflibercept in Diabetic Macular Edema
NCT07705607Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
A Phase 3 trial of tiespectus in diabetic macular edema (DME), sponsored by Merck & Co.. Started Sep 2026; status: recruiting.
02
Drugs
tiespectus
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07705607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07705607.